Репозиторий Университета

© 2018 All-Russian Public Organization Antihypertensive League. All Rights Reserved. objective. To investigate the serum levels of galectin-3 in patients with metabolic syndrome (MS) and in patients with combination of MS and left ventricular hypertrophy (LVH), as well as to define the role of this marker of fibrosis in MS. design and methods. The study included 43 patients with MS (33 patients had LVH), and 33 patients of comparable age without MS (LVH was diagnosed in 10). The level of serum galectin-3 was determined by enzyme immunoassay kits Platinum ELISA. Results. The average level of galectin-3 in the MS group was significantly higher (1,89 ± 1,71 ng/ml), compared to the group without MS (1,03 ± 0,22 ng/ml, p = 0,006). The study showed a positive correlation between the level of galectin-3 and LVH (r = 0,323, p = 0,004). The mean value of galectin-3 in patients with no evidence of LVH was 1,2 ± 0,76 ng/ml, in patients with LVH — 2,1 ± 2,02 ng/ml. conclusions. In patients with MS the level of galectin-3 was higher than in patients without MS, and in patients with MS and concomitant LVH it was higher than in patients without LVH. In patients with MS and LVH increased galectin-3 levels may indicate the severity of myocardial fibrosis and help for prognosis evaluation.